Angelina Pharma To Buy Catalyst For $4.1B; Catalyst Also Settles FIRDAPSE Patent Litigation

Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at about $4.1 billion (€3.5 billion). The boards of both companies unanimously approved the transaction, indicating a clear path to closing. The deal is a material takeover premium event and could support Catalyst shares.

Analysis

Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for $31.50 per share in cash, valuing the company at about $4.1 billion (€3.5 billion). The boards of both companies unanimously approved the transaction, indicating a clear path to closing. The deal is a material takeover premium event and could support Catalyst shares.